0.10
-2.04%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Proteomics International Laboratories
Its shares trade on ASX under the ticker PIQ.AX. It has been listed since 16 April 2015. In the fiscal year to 30 June 2026, it reported revenue of A$278,015 and a net loss of A$8.6m. At that date it held total assets of A$8.9m and shareholders' equity of A$5.8m.
Proteomics International Laboratories Ltd. is a medical technology company which operates at the forefront of predictive diagnostics and bio-analytical services. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2015-04-16. The firm is engaged in predictive diagnostics and bio-analytical services. The firm specializes in proteomics, the study of the structure and function of proteins. The firm focuses on developing and commercializing diagnostic tests for chronic diseases. The firm operates in three business units unified by a technology platform: PromarkerD, Diagnostics and Analytical Services. The PromarkerD test system is a blood test that assess the risk of diabetic kidney disease (DKD) in patients with type 2 diabetes. Diagnostics includes Promarker platform, used to discover, verify, and analytically validate the panel of protein biomarkers for diabetic kidney disease. Its Analytical Services includes a proteomics-based technology platform, used to test, and validate the protein composition of varied range of products.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 16 Apr 2015
- Website
- proteomics.com.au ↗
Leadership
Pay as last reported
- Dr. James WilliamsNon-Executive Independent Chairman of the Board
- Ms. Jacqueline GrayChief Financial Officer$288,189
- Dr. Richard LipscombeManaging Director, Executive Director$330,000
- Dr. Scott BringansHead - Research
- Dr. Javed KhanBusiness Manager - Analytical Services
- Mr. Vikesh MalikChief Commercialisation Officer$393,079
- Mr. Chuck MorrisonHead - Business Development
- Dr. Kirsten PetersHead - Clinical Studies
- Dr. Pearl TanHead - Logistics
- Mr. Timothy LuscombeJoint Company Secretary
- Mr. David WoodJoint Company Secretary
- Mr. Aaron BrinkworthNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Proteomics International Laboratories Ltd. develops PromarkerD for diabetic kidney disease risk assessment.
- The company's Analytical Services test protein composition for diverse products using proteomics.
- PromarkerD is a blood test assessing diabetic kidney disease risk in type 2 diabetes patients.
Weaknesses
- The company's IPO was on 16 April 2015, a relatively recent listing.
- Proteomics International operates in Nedlands, Western Australia, a limited geographic focus.
- The firm's business units are unified by a technology platform but lack diversification.
Opportunities
- The firm's PromarkerD test system targets the growing diabetic kidney disease market.
- Proteomics International's Analytical Services can expand into new product testing segments.
- The company's focus on chronic disease diagnostics aligns with global health trends.
Threats
- The firm's reliance on proteomics technology may face competition from emerging diagnostic methods.
- Proteomics International's focus on diabetic kidney disease could be impacted by changes in healthcare policies.
- The company's limited geographic presence in Nedlands, Western Australia, restricts market reach.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.